Pulmonary Arterial Hypertension Market Offers Opportunity for New and Established Agents

Pulmonary arterial hypertension (PAH) is a rare but fatal disease that severely compromises pulmonary and cardiovascular function. New treatment guidelines and increasing awareness of PAH are rapidly expanding the treatable patient population. Once the exclusive domain of specialty pharma and small biotech firms, PAH is now attracting the attention of a wider scope of companies looking to enter this compact but lucrative market. Get the Answers You Need to Shape Your Strategy Actelion's Tracleer (bosentan) was the fi rst oral drug to gain widespread approval for PAH and is currently the dominant player in the PAH market. However, a signifi cant need for conveniently formulated, effi cacious, and reasonably priced alternatives remains. Which agents-established and emerging-are poised to challenge Tracleer? A growing treatable patient population and a shift from monotherapy to a multimodal treatment approach are expanding the PAH market. What other attractive qualities does the PAH market have, and what opportunities does it present for drug manufacturers? Pfizer has expanded the reach of its lifestyle drug Viagra (sildenafi l) by gaining approval to include PAH in its list of indications. Which other manufacturers plan to follow the same strategy with their established therapies? Please note: the PDF e-mail from publisher version of this report is for a global site license.

Additional Information

Companies
Actelion
Astellas Pharma
Bayer-Schering AG
Biogen Idec
Cotherix
Eli Lilly
Encysive
Epix
Forest
Gilead Sciences
GlaxoSmithKline
ICOS
Kaken Pharmaceuticals
Lundbeck
mondoBiotech
Myogen
Novartis
Pfi zer
PR Pharmaceuticals
United Therapeutics